The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan ®

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue 1, 2012, Pages 13-20

  Sasso, M ^a   Miette, V ^a   Sandrin, L ^a   Beaugrand, M ^b  

^a R and D Department   (France)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER ENZYME;

ALCOHOL CONSUMPTION; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED ATTENUATION PARAMETER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG INDUCED DISEASE; ELASTOGRAPHY; FOLLOW UP; HEMOCHROMATOSIS; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER SURGERY; LIVER TRANSPLANTATION; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; SHORT SURVEY; STEATOSIS; TREATMENT RESPONSE; ULTRASOUND; VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY;

DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 84856708238     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.08.001     Document Type: Short Survey

References (76)

1. Farrell G.C. Fatty liver disease: NASH and related disorders Malden 2004, Blackwell Publishing, MA, USA.
2. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116(6):1413-1419.
3. Powell E.E., Jonsson J.R., Clouston A.D. Steatosis: co-factor in other liver diseases. Hepatology 2005, 42(1):5-13.
4. Bravo A.A., Sheth S.G., Chopra S. Liver biopsy. N Engl J Med 2001, 344(7):495-500.
5. Schwenzer N.F., Springer F., Schraml C., Stefan N., Machann J., Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009, 51(3):433-445.
6. Sandrin L., Fourquet B., Hasquenoph J.M., Yon S., Fournier C., Mal F., et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003, 29(12):1705-1713.
7. Sasso M., Beaugrand M., de Ledinghen V., Douvin C., Marcellin P., Poupon R., et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010, 36(11):1825-1835.
8. Nomura H., Kashiwagi S., Hayashi J., Kajiyama W., Tani S., Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988, 27(2):142-149.
9. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132(2):112-117.
10. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
11. Leandro G., Mangia A., Hui J., Fabris P., Rubbia-Brandt L., Colloredo G., et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006, 130(6):1636-1642.
12. Asselah T., Rubbia-Brandt L., Marcellin P., Negro F. Steatosis in chronic hepatitis C: why does it really matter?. Gut 2006, 55(1):123-130.
13. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl. 1):S99-S112.
14. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121(1):91-100.
15. Gholam P.M., Flancbaum L., Machan J.T., Charney D.A., Kotler D.P. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007, 102(2):399-408.
16. Ratziu V., Bonyhay L., Di Martino V., Charlotte F., Cavallaro L., Sayegh-Tainturier M.H., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002, 35(6):1485-1493.
17. Hui J.M., Kench J.G., Chitturi S., Sud A., Farrell G.C., Byth K., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003, 38(2):420-427.
18. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123(1):134-140.
19. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51(5):1820-1832.
20. Paradis V., Zalinski S., Chelbi E., Guedj N., Degos F., Vilgrain V., et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009, 49(3):851-859.
21. Persico M, Iolascon A. Steatosis as a co-factor in chronic liver diseases. World J Gastroenterol;16(10):1171-1176.
22. Powell E.E., Ali A., Clouston A.D., Dixon J.L., Lincoln D.J., Purdie D.M., et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 2005, 129(6):1937-1943.
23. Poynard T., Ratziu V., McHutchison J., Manns M., Goodman Z., Zeuzem S., et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38(1):75-85.
24. Harrison S.A., Brunt E.M., Qazi R.A., Oliver D.A., Neuschwander-Tetri B.A., Di Bisceglie A.M., et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005, 3(6):604-609.
25. Adinolfi L.E., Gambardella M., Andreana A., Tripodi M.F., Utili R., Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001, 33(6):1358-1364.
26. Castera L., Hezode C., Roudot-Thoraval F., Bastie A., Zafrani E.S., Pawlotsky J.M., et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003, 52(2):288-292.
27. Fartoux L., Chazouilleres O., Wendum D., Poupon R., Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005, 41(1):82-87.
28. Ohata K., Hamasaki K., Toriyama K., Matsumoto K., Saeki A., Yanagi K., et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97(12):3036-3043.
29. Kurosaki M., Hosokawa T., Matsunaga K., Hirayama I., Tanaka T., Sato M., et al. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. Hepatol Res 2010, 40(9):870-877.
30. McCormack L., Petrowsky H., Jochum W., Furrer K., Clavien P.A. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 2007, 245(6):923-930.
31. Grant A., Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of gastroenterology. Gut 1999, 45(Suppl. 4):1-11.
32. Nugent C., Younossi Z.M. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2007, 4(8):432-441.
33. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128(7):1898-1906.
34. Merriman R.B., Ferrell L.D., Patti M.G., Weston S.R., Pabst M.S., Aouizerat B.E., et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006, 44(4):874-880.
35. Brunt E.M. Do you see what I see? The role of quality histopathology in scientific study. Hepatology 2008, 47(3):771-774.
36. Bedossa P., Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009, 50(1):1-3.
37. El-Badry A.M., Breitenstein S., Jochum W., Washington K., Paradis V., Rubbia-Brandt L., et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2009, 250(5):691-697.
38. Regev A., Berho M., Jeffers L.J., Milikowski C., Molina E.G., Pyrsopoulos N.T., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97(10):2614-2618.
39. DiDonato D., Brasaemle D.L. Fixation methods for the study of lipid droplets by immunofluorescence microscopy. J Histochem Cytochem 2003, 51(6):773-780.
40. Fukumoto S., Fujimoto T. Deformation of lipid droplets in fixed samples. Histochem Cell Biol 2002, 118(5):423-428.
41. Angulo P., Lindor K.D. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002, 17 Suppl:S186-S190.
42. Clark J.M., Brancati F.L., Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology 2002, 122(6):1649-1657.
43. Poynard T., Ratziu V., Naveau S., Thabut D., Charlotte F., Messous D., et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005, 4(10):10.
44. Bedogni G., Bellentani S., Miglioli L., Masutti F., Passalacqua M., Castiglione A., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2010, 6:33.
45. Kotronen A., Peltonen M., Hakkarainen A., Sevastianova K., Bergholm R., Johansson L.M., et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009, 137(3):865-872.
46. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010, 53(2):372-384.
47. Mehta S.R., Thomas E.L., Bell J.D., Johnston D.G., Taylor-Robinson S.D. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 2008, 14(22):3476-3483.
48. Hepburn M.J., Vos J.A., Fillman E.P., Lawitz E.J. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterol 2005, 5:14.
49. Lee S.S., Park S.H., Kim H.J., Kim S.Y., Kim M.Y., Kim D.Y., et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 2010, 52(4):579-585.
50. Wallace D.F., Subramaniam V.N. Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. Biochim Biophys Acta 2009, 1790(7):663-670.
51. McPherson S., Jonsson J.R., Cowin G.J., O'Rourke P., Clouston A.D., Volp A., et al. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. J Hepatol 2009, 51(2):389-397.
52. Guiu B., Loffroy R., Hillon P., Petit J.M. Magnetic resonance imaging and spectroscopy for quantification of hepatic steatosis: urgent need for standardization!. J Hepatol 2009, 51(6):1082-1083. [author reply 1083-1084].
53. Ziol M., Handra-Luca A., Kettaneh A., Christidis C., Mal F., Kazemi F., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005, 41(1):48-54.
54. Marcellin P., Ziol M., Bedossa P., Douvin C., Poupon R., de Ledinghen V., et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009, 29(2):242-247.
55. Corpechot C., El Naggar A., Poujol-Robert A., Ziol M., Wendum D., Chazouilleres O., et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006, 43(5):1118-1124.
56. Nahon P., Kettaneh A., Tengher-Barna I., Ziol M., de Ledinghen V., Douvin C., et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008, 49(6):1062-1068.
57. Wong V.W., Vergniol J., Wong G.L., Foucher J., Chan H.L., Le Bail B., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in non-alcoholic liver disease. Hepatology 2010, 51(2):454-462.
58. Szabo T.L. Diagnostic ultrasound imaging: inside out 2004, Elsevier Academic Press.
59. Bushberg J.T. The essential physics of medical imaging. 2nd Edition 2001, Lippincott Williams & Wilkins, Philadelphia, Pa.; London.
60. Kuc R. Clinical application of an ultrasound attenuation coefficient estimation technique for liver pathology characterization. IEEE Trans Biomed Eng 1980, 27(6):312-319.
61. Fink M., Hottier F., Cardoso J.F. Ultrasonic signal processing for in vivo attenuation measurement: short time Fourier analysis. Ultrason Imaging 1983, 5(2):117-135.
62. Maklad N.F., Ophir J., Balsara V. Attenuation of ultrasound in normal liver and diffuse liver disease in vivo. Ultrason Imaging 1984, 6(2):117-125.
63. Taylor K.J., Riely C.A., Hammers L., Flax S., Weltin G., Garcia-Tsao G., et al. Quantitative US attenuation in normal liver and in patients with diffuse liver disease: importance of fat. Radiology 1986, 160(1):65-71.
64. Garra B.S., Insana M.F., Shawker T.H., Russell M.A. Quantitative estimation of liver attenuation and echogenicity: normal state versus diffuse liver disease. Radiology 1987, 162(1 Pt 1):61-67.
65. Wilson L.S., Robinson D.E., Griffiths K.A., Manoharan A., Doust B.D. Evaluation of ultrasonic attenuation in diffuse diseases of spleen and liver. Ultrason Imaging 1987, 9(4):236-247.
66. Lu Z.F., Zagzebski J.A., Lee F.T. Ultrasound backscatter and attenuation in human liver with diffuse disease. Ultrasound Med Biol 1999, 25(7):1047-1054.
67. Fujii Y., Taniguchi N., Itoh K., Shigeta K., Wang Y., Tsao J.W., et al. A new method for attenuation coefficient measurement in the liver: comparison with the spectral shift central frequency method. J Ultrasound Med 2002, 21(7):783-788.
68. Bedossa P., Poynard T. The Metavir cooperative study group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996, 24(2):289-293.
69. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94(9):2467-2474.
70. de Ledinghen V, Le Bail B, Vergniol J, Foucher J, Merrouche W, Sandrin L, et al. Non invasive diagnosis of steatosis using CAP by Fibroscan. A prospective study, In: Conference of the European Association for the study of the liver (EASL), Berlin, Germany; 2011.
71. Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, et al. Novel Controlled Attenuation Parameter (CAP) for non-invasive assessment of steatosis using Fibroscan®: performance in chronic hepatitis C. J Viral Hepatitis 2011; in press.
72. Cardoso AC, Sasso M, Miette V, Fournier C, Sandrin L, Beaugrand M, et al. Controlled attenuation parameter: a novel FibroScan®-based tool to detect and quantify steatosis in chronic hepatitis B, In: Liver meeting of the American association for the study of liver disease (AASLD), Boston, MA, USA; 2010.
73. Beaugrand M, Tengher-Barna I, Ziol M, Nahon P, De Ledinghen V, Douvin C, et al. CAP: a novel non-invasive tool for the evaluation of alcohol induced steatosis, In: European Association for the study of liver (EASL) monothematic conference on alcoholic liver disease, Athens, Greece; 2010.
74. Beaugrand M, Ziol M, De Ledinghen V, Douvin C, Fournier C, Sandrin L, et al. Controlled attenuation parameter for the detection and quantification of steatosis - preliminary study in an alcoholic and non-alcoholic steato-hepatitis cohort, In: Conference of the Asian Pacific association for the study of the Liver (APASL), Beijing, China; 2010.
75. de Ledinghen V., Vergniol J., Foucher J., El-Hajbi F., Merrouche W., Rigalleau V. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int 2010, 30(7):1043-1048.
76. Myers R, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, et al. Feasibility and diagnostic performance of the Fibroscan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2011; in press.